J&J’s next myeloma drug, Argenx’s second act and a new question for Bluebird: 3 ASH takeaways

J&J’s therapy, called talquetamab, is a bispecific antibody aimed at both GPRC5D and a protein expressed by immune cells. Study results presented on Saturday and published in The New England Journal of Medicine suggest it could be the next promising drug to emerge in multiple myeloma — an area already of intense drugmaker interest.